Physician profile

Vance Gardner

Orthopaedic Surgery of the Spine · Irvine, CA

NPI 1568885036

$3,973.38

in general payments reported to CMS, 2019-2025

7 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$44.01

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Surgalign Spine Technologies, INC. $3,434.62 2021-2022
Pacira Pharmaceuticals Incorporated $209.57 2019-2020
Saxum Surgical, INC. $152.95 2022
Stryker Corporation $87.08 2022-2023 Aequalis Perform
Kaleo, INC. $46.15 2019
Emergent Biosolutions INC. $23.19 2019
Myoscience INC. $19.82 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Vance Gardner

$3,973.38

in general payments reported 2019-2025

Years
2019-2023
Top company
Surgalign Spine Technologies, INC.

https://glasscript.com/doctor/778257/vance-gardner

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.